Incyte (INCY.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec9

Citizens Maintains Incyte's Market Performance Rating

12:32

Dec8

Inteum Therapeutics INCA033989 reports positive data at ASH and receives FDA Breakthrough Therapy Designation

21:43

Wells Fargo Raises Incyte's Target Price

16:36

Barclays analyst maintains buy rating for InSightec

08:47

Dec7

FDA Grants Incyte's INCA033989 Breakthrough Therapy Designation

14:30

Incyte Announces Positive Phase 1 Clinical Trial Results for INCA033989

14:30

Schedules & Filings

Schedules

Filings

Oct28

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 1.366 B, Net Income 424.17 M, EPS 2.11

Jul29

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.216 B, Net Income 405 M, EPS 2.04

Apr29

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 1.053 B, Net Income 158.2 M, EPS 0.8

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More